Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBITDA Margin: 2012-2025

Historic EBITDA Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -121.56%.

  • Enanta Pharmaceuticals' EBITDA Margin rose 8282.00% to -121.56% in Q3 2025 from the same period last year, while for Sep 2025 it was -130.65%, marking a year-over-year increase of 4927.00%. This contributed to the annual value of -130.65% for FY2025, which is 4927.00% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported EBITDA Margin of -121.56% as of Q3 2025, which was down 17.83% from -103.16% recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' EBITDA Margin registered a high of -103.16% during Q2 2025, and its lowest value of -221.70% during Q1 2023.
  • Moreover, its 3-year median value for EBITDA Margin was -164.32% (2025), whereas its average is -166.61%.
  • Per our database at Business Quant, Enanta Pharmaceuticals' EBITDA Margin slumped by 10,453bps in 2021 and then soared by 8,282bps in 2025.
  • Enanta Pharmaceuticals' EBITDA Margin (Quarterly) stood at -109.99% in 2021, then plummeted by 1,727bps to -127.25% in 2022, then tumbled by 6,652bps to -193.78% in 2023, then surged by 5,496bps to -138.82% in 2024, then skyrocketed by 8,282bps to -121.56% in 2025.
  • Its last three reported values are -121.56% in Q3 2025, -103.16% for Q2 2025, and -164.32% during Q1 2025.